Cognition Therapeutics Q2 net loss $6.7M; cash runway into Q2 2026; clinical milestones

COGNITION THERAPEUTICS INC

2025-Q2 EPS reported -$0.24

Net loss of $6.7M ($0.11 per share) vs. $7.0M ($0.18 per share) in Q2 2024.
Cash and equivalents $11.6M; plus $41.9M in NIA grant funds; runway into Q2 2026.
Surpassed 50% enrollment in Phase 2 START study of zervimesine in early Alzheimer's.
EOP2 meeting with FDA held; breakthrough designation application for zervimesine in DLB pending.
Positive Phase 2 dry AMD data showed 28.6% reduction in GA lesion growth at 18 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.